Buy Rating for Abeona Therapeutics Driven by FDA Approval and Strong Market Potential of ZEVASKYN

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report), with a price target of $20.00.

Ram Selvaraju’s rating is based on the recent FDA approval of Abeona Therapeutics’ lead candidate, prademagene zamikeracel (pz-cel), now marketed as ZEVASKYN. The approval was timely and the drug’s pricing exceeded initial expectations, suggesting strong market potential. Abeona’s strategic plan involves establishing several qualified treatment centers across the U.S. to ensure patient access and engage payers, which supports a robust commercial rollout.
Furthermore, the clinical efficacy of ZEVASKYN was demonstrated in the Phase 3 VIITAL study, where it showed significant healing in large chronic wounds associated with recessive dystrophic epidermolysis bullosa (RDEB). With a high list price and anticipated patient uptake, Abeona is projected to achieve substantial sales growth, leading to an increased price target for the stock. These factors contribute to Selvaraju’s Buy rating, reflecting confidence in the company’s future performance.

In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $21.00 price target.